Edition:
India

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

24.12USD
18 Apr 2018
Change (% chg)

$0.19 (+0.79%)
Prev Close
$23.93
Open
$24.13
Day's High
$24.34
Day's Low
$23.75
Volume
32,440
Avg. Vol
112,104
52-wk High
$33.86
52-wk Low
$8.10

Chart for

About

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense... (more)

Overall

Beta: --
Market Cap(Mil.): $1,860.50
Shares Outstanding(Mil.): 66.54
Dividend: --
Yield (%): --

Financials

  AKCA.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -4.36 -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.07

BRIEF-Akcea Posts Q4 Loss Per Share $0.35

* AKCEA REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR FOURTH QUARTER AND YEAR END 2017

27 Feb 2018

BRIEF-Akcea Completes Enrollment In Phase 2B Study Of Akcea-Apo(A)-LRx

* AKCEA COMPLETES ENROLLMENT IN PHASE 2B STUDY OF AKCEA-APO(A)-LRX Source text for Eikon: Further company coverage:

07 Feb 2018

BRIEF-Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen

* Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS

15 Nov 2017

BRIEF-Akcea Therapeutics Q3 loss per share $0.27

* Q3 earnings per share view $-0.19, revenue view $11.9 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

07 Nov 2017

Earnings vs. Estimates